LUPIN Ltd.

739.8.00INR + 13.30 (+ 1.83%) VOLUME : 1814000
    Average Volume
  • 5-Day 1,288,000.00
  • 20-Day 1,532,950.00
  • 3-Months 1,396,850.00

MARKET CLOSED

Price Table

Date Open High GREEN: if High is higher than last 2 days high
RED: if high is lower than last 2 days high
Low GREEN:if Low is higher than last 2 days low
RED: if low is lower than last 2 days low
LTP Close GREEN:if Day's Closing is near the Day's High
RED: if low is lower than last 2 days low
Volume Delivery % 20 Day SMA GREEN: if Day's Closing is above 20-Day SMA
RED: if Day's Closing is below 20-Day SMA
50 Day SMA GREEN: if Day's Closing is above 50-Day SMA
RED: if Day's Closing is below 50-Day SMA
100 Day SMA GREEN: if Day's Closing is above 100-Day SMA
RED: if Day's Closing is below 100-Day SMA
200 Day SMA GREEN: if Day's Closing is above 200-Day SMA
RED: if Day's Closing is below 200-Day SMA
18-Oct-19 726.50 746.15 722.85 739.80 739.10 1,813,831 42% 716.58 736.89 741.61 777.19
17-Oct-19 731.50 732.00 719.00 727.00 726.50 744,122 26% 717.58 737.29 741.79 777.68
16-Oct-19 723.00 735.00 716.80 734.50 732.85 1,140,985 36% 719.15 738.06 742.00 778.34
15-Oct-19 718.00 726.90 711.50 720.25 721.15 1,438,966 37% 720.96 738.45 742.27 778.95
14-Oct-19 704.00 720.40 697.30 715.30 716.40 1,302,216 31% 723.11 739.28 742.59 779.56
11-Oct-19 692.65 704.00 683.00 702.50 701.65 1,131,255 18% 725.24 740.49 743.25 780.20
10-Oct-19 680.00 698.80 676.85 690.55 690.95 1,507,716 36% 728.14 741.92 744.05 780.93

Performance

Key Data

Day High Low Range

Time Lowest Highest
10 AM 722.85 731.60
11 AM 722.85 731.60
12 PM 722.85 735.80
1 PM 722.85 735.80
2 PM 722.85 735.80

Company Profile - LUPIN Ltd.

Lupin limited or LUPIN

It is a transnational company that is engaged in the development of APIs, generic and branded formulations. It is the largest producer of Tuberculosis drugs in the world, having both onshore and offshore presence of its products in about 70 countries. Its manufacturing unit is located in Jammu, Goa, Tarapur, Ankleshwar, Mandideep, Indore, Aurangabad and Kyowa in Japan. All the manufacturing facilities of the company are being approved by several international regulatory agencies such as UK MHRA, US FDA, TGA Australia, WHO, and MCC South Africa.

Some of the Business:

  • In formulations, the company offers a broad spectrum of products for the treatment of CVS, Cephalosporins, CNS, Anti–Asthma, Anti–TB, Diabetology, Dermatology, GI, and more. Also, it constitutes 70% of Lupin’s business. It has its presence in countries such as Europe, the USA, Japan, Australia, and emerging markets of In ... dia and several other countries.
  • In the APIs segment, the company provides the product offerings for the treatment of TB, Cardiovascular, Cephalosporins, and many more.
  • In CRAMS or Contract Research and Manufacturing Services space, the company has acquired Novodigm that is engaged in developing and validating the products.

Some of the Awards:

  • 2011:
  • The Top Indian Pharma company under the ‘Pharmaceuticals’ sector for the Dun & Bradstreet – Rolta Corporate Awards in 2010.
  • The Company was ranked among India's Top 3 'Best Companies to Work For' in Healthcare and Pharma Sector.
  • The Hall of Fame Award by Chemtech Foundation (Leadership and Excellence Awards).
  • IMM or Institute of Marketing and Management Award for Excellence as a Top Organization.
  • The Company is ranked 2nd amongst India's 'Best Companies to Work for' in the Biotechnology and Pharmaceutical Sector.
  • 2010:
  • Received the Indian Pharmaceutical Company of the Year 2010' by Frost & Sullivan India Excellence in Healthcare Awards in 2010.
  • The Best Drug Development Company in Asia' by The New Economy Pharmaceutical & Healthcare Awards in 2010.
  • The Company receives 'The Most Promising Entrant into the Big League' by CNBC India Business Leader Awards in 2010.
  • 2009:
  • International Excellence Award by the Institute of Economic Studies.
  • Exceptional Export Performance Award by Pharmexcil (A Pharmaceuticals Export Promotion Council of India).
  • 2008:
  • 'WalMart Supplier Award of Excellence' for overall commitment, on-time shipping, performance, innovative programs, and the overall partnership.
  • 2007:
  • Amerisource Bergen, as one of the leading wholesalers in the US conferred as the “Best New Manufacturer of the Year, Generics Rx” to the Company.
  • The Cardinal Health conferred two awards – the “Trade Representative of the Year” and the “Quality Supplier Award” to the Company.

Some of the Milestones:

  • 2014:
  • The Company acquires Laboratories Grin S.A. De C.V., Mexico; Specialty Ophthalmic Company; and enters the Market of Latin America.
  • The Company acquires Nanomi B.V. – enters the Complex Injectable Space.
  • 2013:
  • The inauguration of the new Plant located at Nagpur.
  • 2012:
  • The Company launches Generic Geodon Capsules".
  • The Company launches Generic SEROQUEL Tablets.
  • 2011:
  • The Company acquires I'rom Pharmaceuticals via its Japanese Subsidiary.
  • Both Lupin and Medicis Enter in a Joint Development Agreement.
  • The Company acquires Worldwide Rights for the Goanna Brand.
  • 2010 :
  • The Company launched Ilyalgan (sodium hyaluronate), an osteoarthritis drug present in the form of an injectable via leading orthopedics and physiotherapists worldwide.
  • 2009:
  • The Company acquired a specific majority stake in the Multicare Pharmaceuticals Philippines Incorporation.
  • 2008:
  • The Company expanded its product basket in Japan-Kyowa and received 10 product approvals from the Ministry of Health & Labour Welfare in Japan.
  • The Company acquired Hormosan Pharma GmbH, which is a Generic Company in Germany.
  • The Company acquired a stake in Generic Health Private Limited in Australia.
  • The Company acquired Pharma Dynamics in South Africa.
  • 2007:
  • The Company acquired Vadodara based Rubamin Laboratories Ltd (it was rechristened to Novodigm Ltd).
  • It acquired Kyowa Pharmaceutical Industry Company Limited, which is a leading Generic Company in Japan.
  • The commercial production was started at the newly finished dosage facility located at Jammu.
  • The Company received the “Best new manufacturer of the year” award from Amerisource Bergen.
  • 2006:
  • A new facility was being set up in Jammu.
  • The Maiden Bonus share was issued in the ratio of 1:1.
  • The maiden issue of Foreign Currency Convertible Bonds or FCCB aggregating the US $100 mn that is listed on the Singapore Stock Exchange.
  • 2005:
  • The maiden Employees' Stock Option Plan was executed.
  • Both the US FDA and MHRA (UK) approvals were received for the Goa.
  • The US FDA approved a new Lovastatin plant located at Tarapur.
  • 2004:
  • The WHO approval was received for the State of the art formulation Plants located at Goa and Aurangabad.
  • 2003:
  • The Company had successfully executed SAP ERP in the Company to unify entire business functions and processes.
  • Also, introduced collaborative messaging and workflow solutions on the intranet.
  • The US FDA approved the oral Cefaclor injectible Plant in Mandideep.
  • Lupin Pharmaceuticals Inc. USA was formed for the trading, marketing, and developmental activities in the US.
  • 2002:
  • The exports to the Advanced Markets crossed INR 1000 mn.
  • The rising trend of exports as a % of total revenue - up 33% year-over-year.
  • The Patent filings crossed over 100.
  • The five ANDAs were being filed.
  • The new Anti–TB facility was being commissioned in Aurangabad.
  • ORG–Marg rated the Rablet as one of the second-best launches of the FY 2002–03.
  • 2001:
  • It became the only Asian Pharmaceutical company to receive US FDA approvals for its facility of sterile cephalosporin.
  • State of the art US FDA approved oral cephalosporin bulk active plant was being commissioned.
  • The State of the art R&D Centre at Pune was being commissioned.
  • The Company commenced the supply of Cephalosporin bulk actives to its alliance partners in the US.
  • The Company was amalgamated with Lupin Chemicals Limited, whose name was changed to the Lupin Limited.
  • 2000:
  • Also, the US FDA approved the Cefotaxime facility. The Company’s restructuring operations produced favorable results.
  • Work was commenced at the R&D Centre in Pune.